Kailera CMO reports stock option holdings
Kailera Therapeutics, Inc. filed an initial ownership report for Chief Medical Officer Scott M. Wasserman, showing existing stock option holdings in the company.
Rhea-AI Filing Summary
Kailera Therapeutics, Inc. filed an initial ownership report for Chief Medical Officer Scott M. Wasserman, showing existing stock option holdings in the company. These options give him the right to buy common shares at exercise prices of $7.24 and $5.25 per share, with expirations in 2034 and 2035. The footnotes explain that each grant vests 25% on an initial vesting date in 2025 or 2026, then in 36 substantially equal monthly installments, conditioned on his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Wasserman Scott M.
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 862,450 contracts (Direct)
Footnotes (3)
- F1. The options vested and became exercisable as to 25% of the total shares on December 9, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F2. The options vested and became exercisable as to 25% of the total shares on September 30, 2025 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F3. The options vest and become exercisable as to 25% of the total shares on November 5, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Underlying shares grant 1: 147,324 shares
Underlying shares grant 2: 427,960 shares
Underlying shares grant 3: 287,166 shares
+5 more
8 metrics
Underlying shares grant 1
147,324 shares
Stock Option, exercise price $7.24
Underlying shares grant 2
427,960 shares
Stock Option, exercise price $5.25
Underlying shares grant 3
287,166 shares
Stock Option, exercise price $5.25
Exercise price (higher grant)
$7.24/share
Stock Option expiring November 5, 2035
Exercise price (two grants)
$5.25/share
Stock Options expiring December 9, 2034
Option expiration 1
December 9, 2034
Stock Option (right to buy), $5.25 exercise
Option expiration 2
November 5, 2035
Stock Option (right to buy), $7.24 exercise
Initial vesting dates
Sept 30 & Dec 9, 2025; Nov 5, 2026
25% of option shares vest on each initial date
Key Terms
Stock Option (right to buy), Common Stock, vested and became exercisable, substantially equal monthly installments, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vested and became exercisable financial
"The options vested and became exercisable as to 25% of the total shares"
substantially equal monthly installments financial
"thereafter in 36 substantially equal monthly installments"
continued service financial
"subject to the Reporting Person's continued service on each such vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the KLRA Form 3 filing show for Scott M. Wasserman?
The Form 3 shows Chief Medical Officer Scott M. Wasserman’s existing stock option holdings in Kailera Therapeutics. It details option strike prices, expiration dates, and vesting schedules tied to his continued service with the company.
What are the exercise prices of Scott Wasserman’s KLRA stock options?
His reported stock options have exercise prices of $7.24 and $5.25 per share. These prices are fixed in the grants and represent the cost per share if he chooses to exercise the options in the future.
When do Scott Wasserman’s KLRA stock options expire?
The reported stock options expire on December 9, 2034 and November 5, 2035, depending on the grant. He generally must exercise vested portions before these expiration dates for the options to retain their economic value.
How do Scott Wasserman’s KLRA options vest over time?
Each option grant vests 25% on an initial date in 2025 or 2026, then in 36 substantially equal monthly installments. Vesting continues only while Scott Wasserman remains in service with Kailera Therapeutics on each scheduled vesting date.
Does the KLRA Form 3 indicate any recent insider buying or selling?
The filing lists existing stock option holdings rather than new purchases or sales. Transactions are coded as holdings with unknown transaction codes, so it functions mainly as an initial ownership snapshot for the Chief Medical Officer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
